Seven Eight Capital, LP Kymera Therapeutics, Inc. Transaction History
Seven Eight Capital, LP
- $927 Million
- Q1 2024
A detailed history of Seven Eight Capital, LP transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Seven Eight Capital, LP holds 15,963 shares of KYMR stock, worth $482,880. This represents 0.07% of its overall portfolio holdings.
Number of Shares
15,963
Previous 22,416
28.79%
Holding current value
$482,880
Previous $570,000
12.46%
% of portfolio
0.07%
Previous 0.07%
Shares
2 transactions
Others Institutions Holding KYMR
# of Institutions
164Shares Held
63.1MCall Options Held
39.7KPut Options Held
9.7K-
Price T Rowe Associates Inc Baltimore, MD6.33MShares$192 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$181 Million3.05% of portfolio
-
Atlas Venture Life Science Advisors, LLC5.38MShares$163 Million27.05% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$156 Million6.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.77MShares$144 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $1.65B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...